- Strong revenue for the quarter up 43% to $3.6M for Q1 2024 compared to $2.5M for Q1 2023.
- Loss from operations for Q1 2024 was $(0.1)M, an improvement of $0.3M, when compared to Q1 2023.
- Net Loss for Q1 2024 was $(0.3)M
compared to Net Loss of $(0.5)M for
Q1 2023.
- Adjusted EBITDA(1) of $0.1M for Q1 2024, compared to Adjusted
EBITDA(1) loss of $(0.5)M
for Q1 2023, an improvement of $0.6M.
- Adjusted EBITDA Margin(1) of 3% in Q1 2024 compared
to (19)% in Q1 2023.
- ARR([2]) of $11.8M as
of March 31, 2024, an increase of 10%
over the same date in 2023.
MONTREAL, May 15, 2024
/CNW/ - Carebook Technologies Inc. ("Carebook" or
the "Company") (TSXV: CRBK) (OTCPK: CRBKF) (XFRA:
PMM1), a leading Canadian provider of innovative digital health
solutions today announced its results for the quarter ended
March 31, 2024.
"The first quarter of 2024 continues to show strong revenue
growth when compared to the first quarter of 2023 as we completed
several large implementations and helped our clients onboard a
significant amount of users during the last twelve months"
commented Michael Peters, Carebook
CEO. "We were successful delivering 43% year-over-year revenue
growth, which was all organic, while we continued to improve our
margins and operating cash flows. We expect the organic revenue
growth trend to continue into the remainder of 2024 but at a slower
pace, in the next quarters of 2024. We will continue managing cost
with an objective of minimizing cash burn and increasing our profit
margins."
______________________________
|
1 EBITDA and
Adjusted EBITDA are non-IFRS financial measures, and Adjusted
EBITDA Margin is a non-IFRS financial ratio, in each case without a
standardized meaning under IFRS and which may not be comparable to
similar measures or ratios used by other issuers. Please refer to
the sections "Cautionary Note Regarding Non-IFRS Measures, non-IFRS
Ratios and Key Performance Indicators", "Non-IFRS Measures and
Non-IFRS Ratios" and "Non-IFRS Measures and Reconciliation of
Non-IFRS Measures EBITDA and Adjusted EBITDA" for the definitions
of such non-IFRS financial measures and ratio, an explanation of
the usefulness of such non-IFRS financial measures and ratio, and a
reconciliation of non-IFRS financial measures to the most directly
comparable IFRS financial measure.
2 Annual Recurring Revenue or ARR is a key performance
indicator. Please refer to the sections "Cautionary Note Regarding
Non-IFRS Measures, non-IFRS Ratios and Key Performance Indicators"
and "Key Performance Indicators" below for the definition of ARR,
as well as an explanation of the usefulness of such key performance
indicator to the Company.
|
Q1 2024
Highlights
Revenue
Revenue for the quarter ended March 31,
2024 was $3.6M compared to
$2.5M for the quarter ended
March 31, 2023, an increase of 43%
driven by strong organic growth in the pharmacy vertical and a
significant increase in license revenue from CoreHealth offset by a
decrease in license revenue at Infotech. Revenue in the quarter
ended March 31, 2024, was contributed
64% from the employer vertical and 36% from our key customer in the
pharmacy vertical.
Loss from Operations and Total Comprehensive
Loss
Loss from operations for the quarter ended March 31, 2024, was $(0.1)M compared to $(0.4)M incurred in the same period of 2023, an
improvement of $0.3M. The decrease in
loss from operations was due to significantly higher revenue offset
by higher research and development costs and slightly higher sales
and marketing costs.
Total comprehensive loss was $(0.3)M for quarter ended March 31, 2024, compared to a loss of
$(0.5)M for the quarter ended
March 31, 2023. The decrease in
comprehensive loss was also due to significantly higher revenue
offset by higher research and development costs and slightly higher
sales and marketing costs.
Adjusted EBITDA(1)
Adjusted EBITDA(1) for the quarter ended March 31, 2024 was $0.1M compared to an Adjusted
EBITDA(1) loss of $(0.5)M
for the quarter ended March 31, 2023, an improvement of
$0.6M over the same period in 2023.
The corresponding Adjusted EBITDA Margin(1) for
the quarter ended March 31, 2024 was
3% compared to (19)% in the quarter ended March 31, 2023, and represented a meaningful
improvement, demonstrating management's fortitude and discipline to
continue to generate increasing revenue while managing costs to
reach profitability.
Annual Recurring Revenue
ARR(2) was $11.8M as at
March 31, 2024, an increase of
$1.1M, or 10%, compared to an
ARR(2) of $10.7M as at
March 31, 2023. This increase was
primarily driven by new enterprise customers and organic growth
with existing customers. Of the $11.8M of ARR(2) reported, 62%
originated from clients outside of Canada.
Financial Outlook
Carebook's financial outlook continues to be positive for 2024.
The Company is poised to achieve significant revenue growth while
effectively managing its costs and delivering sustained growth in
cashflows. Carebook's strong organic growth and efficient cost
management initiatives will allow the Company to continue to
successfully execute on its strategy. Carebook is expecting
to maintain strong performance in 2024 for the entire Company as a
whole and although actual results may differ, we believe Carebook
is on a course to deliver Adjusted EBITDA(1) break even
or better in fiscal 2024. To complement its organic growth
strategy, Carebook will continue to seek out accretive acquisitions
and partnerships that improve the accessibility, quality, and
functionality of its comprehensive solutions, surrounding
ecosystem, and supporting services. Carebook has adopted a
disciplined approach towards exploring strategic M&A
opportunities in order to grow its reach in other markets and offer
new services to its customer base, while maintaining a focus on its
organic growth. This financial outlook is fully qualified and based
on a number of assumptions and subject to a number of risks
described under the headings "Financial Outlook Assumptions" and
"Notice Regarding Forward-Looking Statements" of this press
release.
Conference Call Details
A conference call will be held at 8:30 AM Eastern
on May 15, 2024 to discuss Carebook's financial results
for the quarter. Participants may join the Company's conference
call by using the following information
Conference Call
Details
|
|
Date
|
Wednesday, May 15,
2024
|
Time:
|
8:30 a.m. Eastern
Time
|
Local:
|
416-764-8659
|
North American Toll
Free:
|
1-888-664-6392
|
RapidConnect
URL:
|
Click here
|
Webcast URL:
|
Click here
|
|
|
Conference
Replay
|
|
Local:
|
416-764-8677
|
North American Toll
Free:
|
1-888-390-0541
|
Entry Code:
|
848463#
|
Expiration
Date:
|
05/22/2024
|
Carebook's interim condensed consolidated financial statements
and accompanying notes, and Management's Discussion and Analysis
for the quarter ended March 31, 2024 are available on the
Company's website at www.carebook.com and on SEDAR+
at www.sedarplus.ca.
Cautionary Note Regarding Non-IFRS Measures, non-IFRS Ratios
and Key Performance Indicators
This press release makes reference to certain non-IFRS measures
and key performance indicators. These measures are not standardized
financial measures under IFRS as issued by the IASB and do not have
a standardized meaning prescribed by IFRS and are therefore
unlikely to be comparable to similar measures presented by other
companies. Rather, these measures are provided as additional
information to complement those IFRS measures by providing further
understanding of our results of operations from management's
perspective. Accordingly, these measures should not be considered
in isolation nor as a substitute for analysis of our financial
information reported under IFRS. We use non-IFRS measures,
including "EBITDA" and "Adjusted EBITDA" and non-IFRS ratios
including "Adjusted EBITDA Margin". This press release also makes
reference to "Annual Recurring Revenue" or "ARR", which is a key
performance indicator used in our industry. These non-IFRS
measures, non-IFRS ratios and key performance indicators are used
to provide investors with supplemental measures of our operating
performance and liquidity and thus highlight trends in our business
that may not otherwise be apparent when relying solely on IFRS
measures. The Company also believes that securities analysts,
investors, and other interested parties frequently use non-IFRS
measures, non-IFRS ratios and key performance indicators in the
evaluation of issuers. The Company's management also uses non-IFRS
measures, non-IFRS ratios and key performance indicators in order
to facilitate operating performance comparisons from period to
period, to prepare annual operating budgets and forecasts, and to
determine components of management and executive compensation. The
key performance indicators used by the Company may be calculated in
a manner different than similar key performance indicators used by
other companies.
Non-IFRS Measures and Non-IFRS Ratios
"Adjusted EBITDA" is defined as EBITDA adjusted for
non-recurring M&A and other transaction costs, certain
non-recurring costs (or savings), share-based compensation, foreign
exchange loss (gain), intangible asset and goodwill impairment,
changes in fair value of warrants or changes in fair value of
contingent consideration. Adjusted EBITDA provides management with
a useful supplemental measure in evaluating the performance of our
operations and provides better transparency into our results of
operations. Adjusted EBITDA indicates our ability to generate
profit from our operations prior to considering our financing
decisions and costs of consuming intangible and capital assets.
"EBITDA" is defined as net income or loss before income tax
expenses, finance costs and depreciation and amortization.
"Adjusted EBITDA Margin" is calculated as Adjusted EBITDA
divided by revenue for the relevant period.
Key Performance Indicators
"Annual Recurring Revenue" or "ARR" represents contracted
software and services revenues that are expected to have a duration
of more than one year, and is equal to the annualized value of
contracted recurring revenue from all clients on our platforms at
the date being measured. Contracted recurring revenue is revenue
generated from clients who are, as of the date being measured,
party to contracts with Carebook that are contributing to revenue
in the calendar month of the date being measured, and also include
revenue from clients who are, as of the date being measured, party
to contracts with Carebook that are to contribute to revenue within
a year of the date being measured. ARR provides a consolidated
measure by which we can monitor the longer-term trends in our
business.
Non-IFRS Measures and Reconciliation of Non-IFRS Measures
EBITDA and Adjusted EBITDA
In
$000s
|
|
|
THREE
MONTHS
ENDED
March 31, 2024
|
|
THREE
MONTHS
ENDED
March 31, 2023
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
$
|
(349)
|
|
$
|
(459)
|
Add:
|
|
|
|
|
|
|
|
Amortization and
depreciation expense
|
|
|
$
|
369
|
|
$
|
421
|
Finance
costs
|
|
|
$
|
382
|
|
$
|
372
|
Other income
(1)
|
|
|
$
|
(6)
|
|
$
|
(14)
|
Income Tax expense
(recovery)
|
|
|
$
|
(162)
|
|
$
|
(320)
|
EBITDA
(2)
|
|
|
$
|
234
|
|
$
|
-
|
Add:
|
|
|
|
|
|
|
|
Share-Based
compensation
|
|
|
$
|
43
|
|
$
|
44
|
Additional One-Time
Costs (Savings) (3)
|
|
|
$
|
(186)
|
|
$
|
(512)
|
Adjusted EBITDA
(3)
|
|
|
$
|
91
|
|
$
|
(468)
|
(1)
|
Other income includes
interest income, finance income, and gain on the disposal of
capital assets.
|
(2)
|
Non-IFRS financial
measures without a standardized definition under IFRS, which may
not be comparable to similar measures used by other issuers. Refer
to the Section "Non-IFRS Measures and Non-IFRS Ratios" of this
press release for an explanation of the composition and usefulness
of these non-IFRS financial measures.
|
(3)
|
Additional One-Time
Costs (Savings) relate to grants received from the Quebec
government and Prompt, a trust agency of the Ministry of Economy,
Innovation and Energy research group in Québec.
|
About Carebook Technologies
Carebook's digital health platform empowers its clients and more
than 4.6 million members to take control of their health journey.
During 2021, the Company completed the acquisitions of InfoTech
Inc. ("InfoTech"), a global leader in health and
productivity risk management, and CoreHealth Technologies Inc.
("CoreHealth"), owner of an industry-leading wellness
platform. In combination, these companies create a comprehensive
digital health platform that includes both assessment tools and the
technology to deliver complementary solutions. Carebook's shares
trade on the TSXV under the symbol "CRBK," on the OTC Markets under
the symbol "CRBKF," and are listed on the Open Market of the
Frankfurt Stock Exchange under the symbol "PMM1."
www.carebook.com
For further information contact:
Carebook Investor Relations Contact:
Olivier Giner, CFO
Email : ir@carebook.com
Telephone: (450) 977-0709
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this news release.
Financial Outlook Assumptions
Our financial outlook is based on a number of assumptions,
including assumptions related to inflation, changes in interest
rates, consumer spending, foreign exchange rates and other
macroeconomic conditions; our major revenue streams remaining in
line with our expectations; customers adopting our solutions at an
average contract value at or above that of our planned levels; our
ability to price our products in line with our expectations and to
achieve suitable margins; our ability to achieve success in the
continued expansion of our product lines and solutions; continued
success in additional product adoption and user base expansion
throughout our customer base; our ability to derive the benefits we
expect from the acquisitions we have completed; our ability to
attract and retain key personnel required to achieve our plans; our
expectations regarding the costs, timing and impact of our cost
reduction initiatives; our ability to manage customer churn and
churn rates remaining at planned levels. Our financial outlook does
not give effect to the potential impact of acquisitions that may be
announced or closed after the date hereof. Our financial outlook,
including the various underlying assumptions, constitutes
forward-looking information and should be read in conjunction with
the cautionary notice on forward-looking statements below. Many
factors may cause our actual results, level of activity,
performance or achievements to differ materially from those
expressed or implied by such forward-looking information.
Notice Regarding Forward-Looking Statements:
This release includes forward-looking information and
forward-looking statements within the meaning of Canadian
securities laws regarding Carebook, its subsidiaries and their
business. Often, but not always, forward-looking information can be
identified by the use of words such as "plans", "is expected",
"expects", "scheduled", "intends", "contemplates", "anticipates",
"believes", "proposes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would", "might" or
"will" be taken, occur or be achieved. Forward-looking information
in this release include statements with respect to revenue, our
2024 full year outlook, the Company's growth strategy, management's
expectations regarding revenue growth and cost management, contract
generation and the overall value of recently signed contracts and
the Company's path to profitability. Such statements are based on
the current expectations of the management of Carebook and are
based on assumptions and subject to risks and uncertainties.
Although the management of Carebook believes that the assumptions
underlying these statements are reasonable, they may prove to be
incorrect, and undue reliance should not be placed on such
forward-looking statements. The forward-looking statements reflect
the Company's current views with respect to future events based on
currently available information and are inherently subject to risks
and uncertainties. The forward-looking events and circumstances
discussed in this release may not occur by certain specified dates
or at all and could differ materially as a result of known and
unknown risk factors and uncertainties affecting the Company,
including economic factors, management's ability to manage and to
operate the business of Carebook, management's ability to identify
attractive M&A opportunities, management's ability to
successfully integrate the Company's completed acquisitions and to
realize the synergies of such acquisitions, management's ability to
successfully complete product studies, the equity markets generally
and risks associated with growth and competition, management's
ability to achieve profitability for the Company, as well as the
risk factors identified in the Company's management's discussion
and analysis for the year ended December 31,
2023, a copy of which can be found on SEDAR+ under the
Company's profile at www.sedarplus.ca. Although Carebook has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward-looking statement can be guaranteed. Except
as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Carebook does not undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
SOURCE Carebook Technologies Inc.